🚀 VC round data is live in beta, check it out!
Novacyt Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novacyt and similar public comparables like ContextVision, CurveBeam AI, NanoRepro, Diagnos and more.
Novacyt Overview
About Novacyt
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
Founded
2006
HQ
Employees
234
Website
Financials (LTM)
EV
$15M
Novacyt Financials
Novacyt reported last 12-month revenue of $28M and negative EBITDA of ($11M).
In the same LTM period, Novacyt generated ($11M) in EBITDA losses.
Revenue (LTM)
Novacyt P&L
In the most recent fiscal year, Novacyt reported revenue of $27M and EBITDA of ($46M).
Novacyt expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $28M | XXX | $27M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $43M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 163% | XXX | XXX | XXX |
| EBITDA | ($11M) | XXX | ($46M) | XXX | XXX | XXX |
| EBITDA Margin | (39%) | XXX | (175%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (85%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($56M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (213%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Novacyt Stock Performance
Novacyt has current market cap of $32M, and enterprise value of $15M.
Market Cap Evolution
Novacyt's stock price is $0.44.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15M | $32M | -1.3% | XXX | XXX | XXX | $-0.78 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovacyt Valuation Multiples
Novacyt trades at 0.5x EV/Revenue multiple, and (1.4x) EV/EBITDA.
EV / Revenue (LTM)
Novacyt Financial Valuation Multiples
As of April 20, 2026, Novacyt has market cap of $32M and EV of $15M.
Equity research analysts estimate Novacyt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novacyt has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV (current) | $15M | XXX | $15M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | (1.4x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.3x | XXX | XXX | XXX |
| P/E | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novacyt Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Novacyt Margins & Growth Rates
Novacyt's revenue in the last 12 month grew by 15%.
Novacyt's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Novacyt's rule of 40 is (15%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novacyt's rule of X is 7% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Novacyt Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | (39%) | XXX | (175%) | XXX | XXX | XXX |
| EBITDA Growth | (29%) | XXX | (75%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (15%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 205% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 248% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Novacyt Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novacyt | XXX | XXX | XXX | XXX | XXX | XXX |
| ContextVision | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NanoRepro | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnos | XXX | XXX | XXX | XXX | XXX | XXX |
| EBM Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novacyt M&A Activity
Novacyt acquired XXX companies to date.
Last acquisition by Novacyt was on XXXXXXXX, XXXXX. Novacyt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Novacyt
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNovacyt Investment Activity
Novacyt invested in XXX companies to date.
Novacyt made its latest investment on XXXXXXXX, XXXXX. Novacyt invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Novacyt
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novacyt
| When was Novacyt founded? | Novacyt was founded in 2006. |
| Where is Novacyt headquartered? | Novacyt is headquartered in France. |
| How many employees does Novacyt have? | As of today, Novacyt has over 234 employees. |
| Who is the CEO of Novacyt? | Novacyt's CEO is Lyn Dafydd Rees. |
| Is Novacyt publicly listed? | Yes, Novacyt is a public company listed on Euronext Paris. |
| What is the stock symbol of Novacyt? | Novacyt trades under ALNOV ticker. |
| When did Novacyt go public? | Novacyt went public in 2012. |
| Who are competitors of Novacyt? | Novacyt main competitors are ContextVision, CurveBeam AI, NanoRepro, Diagnos. |
| What is the current market cap of Novacyt? | Novacyt's current market cap is $32M. |
| What is the current revenue of Novacyt? | Novacyt's last 12 months revenue is $28M. |
| What is the current revenue growth of Novacyt? | Novacyt revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Novacyt? | Current revenue multiple of Novacyt is 0.5x. |
| Is Novacyt profitable? | No, Novacyt is not profitable. |
| What is the current EBITDA of Novacyt? | Novacyt has negative EBITDA and is not profitable. |
| What is Novacyt's EBITDA margin? | Novacyt's last 12 months EBITDA margin is (39%). |
| What is the current EV/EBITDA multiple of Novacyt? | Current EBITDA multiple of Novacyt is (1.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.